Navigation Links
Nektar Therapeutics Reports First Quarter 2011 Financial Results
Date:4/27/2011

s; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(650) 631-4954Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries:Karen Bergman/BCC Partners

(650) 575-1509 Michelle Corral/BCC Partners

(415) 794-8662NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSMarch 31, 2011December 31, 201
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dennis Winger Joins Nektar Therapeutics Board of Directors
2. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
3. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
5. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
9. Nektar Therapeutics Reports First Quarter 2009 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (PRWEB) July 23, 2014 International research ... announced that its biobanking project, Provia Laboratories , ... its growing Advisory Board. Scott Wolf , CEO ... have Dr. Vaught onboard with Provia’s ever-expanding Advisory Board. ... that Provia’s management team brings to this field, should ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are ... for the long term. They are the first functional ... sustained energy as an alternative to the temporary fix ... on Indiegogo on July 29, 2014, with hopes to ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... de julio de 2014 ADB International ... ha anunciado hoy una asociación con Austen BioInnovation ... o el Instituto), para el propósito de llevar ... terapia de señal bioeléctrica (el E-QURE BST Device), ... que tiene una importante experiencia en cicatrización de ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
Breaking Biology Technology:Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Entomologists at the University of California, Riverside working on ... of compounds that could pave the way for developing inexpensive ... other deadly tropical diseases. When fruit flies undergo stress, ... a warning to other fruit flies that danger or predators ...
... HARBIN, China, Aug. 26 ... One Medical" or "the Company") (Nasdaq: ... over-the-counter,drugs in the People,s Republic of China ("PRC"), ... been raised with respect to financial reports filed,with ...
... , PARIS, August 26 , - Net Profit Up 11%, - Strong Research ... The Board of Directors, meeting on 25 August 2009 under the chairmanship,of Albert Saporta approved the 2009 half year financial ... 08/07 H1 2009, ... Var.% %CA, Sales ...
Cached Biology Technology:Discovery of natural odors could help develop mosquito repellents 2Discovery of natural odors could help develop mosquito repellents 3China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 2China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 4
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today announced ... University of Massachusetts Amherst School of Public Health ... $700,000 Science to Achieve Results (STAR) grant to ... Native subsistence hunters in subarctic North America to ... and to provide culturally-relevant recommendations for mitigation. , ...
(Date:7/23/2014)... Mass. Honey bees, especially the young, are highly ... work together to maintain temperatures within a narrow range. ... biologist at Tufts University,s School of Arts and Sciences, ... excess heat within a hive in process similar to ... blood vessels and skin. , "This study shows ...
(Date:7/23/2014)... cultured from cystic fibrosis patients, scientists at the UNC ... have shown that a new CF drug counteracts the ... The finding, published today in the journal Science ... becomes unstable and loses its ability to function properly ... research offers several insights into how novel CF pharmacotherapies ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3How honey bees stay cool 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... in extreme cold, scientists no longer have to go ... Bacteria previously isolated from polar climates, and have properties ... been isolated from soil in temperate environments. , Professor ... have developed a technique to isolate bacteria which have ...
... the four bacterial surface proteins that generate the ... University of Chicago have created a vaccine that ... strains of Staphylococcus aureus, the most common cause ... of community-associated illness. , The vaccine protected ...
... The repeated copying of a small segment of DNA in ... to the transition of ancient animals from sea to land, ... discovery is "tantalizing evidence" that copied DNA elements known as ... the director of the research, Howard Hughes Medical Institute investigator ...
Cached Biology News:MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3Mobile DNA part of evolution's toolbox 2Mobile DNA part of evolution's toolbox 3Mobile DNA part of evolution's toolbox 4
... Works fast and effectively in tubes and ... and simple, one tube, one and a half ... to clean up or concentrate any type of ... primers, primer dimers or dNTPs (labelled or unlabelled). ...
... holds 96 x 0.2 ml tubes or ... incorporates a thumbwheel to adjust height and ... oil-free cycling. Peltier heat pumps produce uniform, ... rates of up to 1.4 degrees C ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
Sf21 Insect Cells (Live) in Max-XP Medium...
Biology Products: